Ersilia M. DeFilippis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ersilia M. DeFilippis has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Brian Paul Bosworth
Department of Medicine NYU Langone Health New York, NY United States
2 shared publications Ellen J. Scherl
Department of Medicine, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, New York, USA
2 shared publicationsAdam Steinlauf
Department of Gastroenterology and Hepatology Weill Cornell Medical College/New York Presbyterian Hospital New York NY USA
1 shared publicationAmanda DeMauro
Department of Medicine, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, New York, USA
1 shared publicationCynthia Magro
Weill Cornell Medical College
1 shared publicationDana Leifer
Department of Neurology Weill Cornell Medical College/New York Presbyterian Hospital New York NY USA
1 shared publication
Latest Publications
- 1 February 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 267-271
Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience
Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients’ electronic medical records were reviewed. Median age at diagnosis was 43 (18–71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.
- 1 February 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 267-271
Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience
Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients’ electronic medical records were reviewed. Median age at diagnosis was 43 (18–71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.
- 1 July 2015
- Published by Wiley in Journal of Digestive Diseases
- Vol. 16 (7) , 416-419
Pneumocystis jiroveci pneumonia with recurrent pneumothorax requiring pleurodesis in inflammatory bowel disease
- 1 July 2015
- Published by Wiley in Journal of Digestive Diseases
- Vol. 16 (7) , 416-419
Pneumocystis jiroveci pneumonia with recurrent pneumothorax requiring pleurodesis in inflammatory bowel disease
- 22 May 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (10) , 2873-2880
Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease
Nearly one-third of patients with inflammatory bowel disease (IBD) have abnormal liver tests, which can be indicative of underlying hepatic disease. Primary sclerosing cholangitis has a clear association with ulcerative colitis, but other autoimmune disorders such as autoimmune hepatitis (AIH) have also been associated with IBD. AIH may also occur in the setting of an overlap syndrome or in the setting of medications, particularly tumor necrosis factor alpha inhibitors. Importantly, some studies have shown that IBD patients with AIH fail treatment more frequently than IBD patients without AIH. This review will focus on the clinical characteristics, diagnosis, and management of autoimmune hepatitis in inflammatory bowel disease patients.
- 22 May 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (10) , 2873-2880
Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease
Nearly one-third of patients with inflammatory bowel disease (IBD) have abnormal liver tests, which can be indicative of underlying hepatic disease. Primary sclerosing cholangitis has a clear association with ulcerative colitis, but other autoimmune disorders such as autoimmune hepatitis (AIH) have also been associated with IBD. AIH may also occur in the setting of an overlap syndrome or in the setting of medications, particularly tumor necrosis factor alpha inhibitors. Importantly, some studies have shown that IBD patients with AIH fail treatment more frequently than IBD patients without AIH. This review will focus on the clinical characteristics, diagnosis, and management of autoimmune hepatitis in inflammatory bowel disease patients.
- 24 February 2015
- Published by Wiley in Journal of Digestive Diseases
- Vol. 16 (2) , 104-108
Cerebral venous thrombosis in inflammatory bowel disease
Cerebral venous thrombosis (CVT) is a rare but devastating complication of inflammatory bowel disease (IBD). Here we describe six IBD patients with cerebral venous thrombosis. The patients presented with hours to days of headache and were found to have venous thrombosis on imaging. Four of the six patients had ulcerative colitis and two had Crohn's disease. All six patients were treated with therapeutic anticoagulation. There were two deaths; one patient became comatose and died despite anticoagulation while the other recovered well from the sinus thrombosis but died after a bowel perforation 3 weeks later. This case series demonstrates the critical need for early recognition of neurological symptoms in patients with IBD during disease flares. It is important to recognize the clinical signs in order to start anticoagulation expeditiously and improve neurological outcomes.
- 24 February 2015
- Published by Wiley in Journal of Digestive Diseases
- Vol. 16 (2) , 104-108
Cerebral venous thrombosis in inflammatory bowel disease
Cerebral venous thrombosis (CVT) is a rare but devastating complication of inflammatory bowel disease (IBD). Here we describe six IBD patients with cerebral venous thrombosis. The patients presented with hours to days of headache and were found to have venous thrombosis on imaging. Four of the six patients had ulcerative colitis and two had Crohn's disease. All six patients were treated with therapeutic anticoagulation. There were two deaths; one patient became comatose and died despite anticoagulation while the other recovered well from the sinus thrombosis but died after a bowel perforation 3 weeks later. This case series demonstrates the critical need for early recognition of neurological symptoms in patients with IBD during disease flares. It is important to recognize the clinical signs in order to start anticoagulation expeditiously and improve neurological outcomes.
- 1 December 2014
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 89 (12) , 1592
The Things We Forget to Ask
- 1 December 2014
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 89 (12) , 1592
The Things We Forget to Ask
- 19 September 2014
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 7 (5) , 410-413
Bowel-associated dermatosis − arthritis syndrome in a patient with ulcerative colitis: an extraintestinal manifestation of inflammatory bowel disease
Bowel-associated dermatosis − arthritis syndrome (BADAS) is a neutrophilic dermatosis characterized by cutaneous lesions that begin as erythematous macules and progress to vesiculopustular eruptions. It has been described in patients with inflammatory bowel disease as well as those who have undergone various intestinal surgeries. Pathologically, the lesions show features of vasculitis without fibrinoid necrosis. In a patient with diagnosed inflammatory bowel disease, these neutrophilic dermatoses should be viewed as external signals of bowel inflammation. Management requires long-term treatment of the underlying disease. We report a case of BADAS in a patient with ulcerative colitis in which the skin lesions were associated with increased colonic inflammation.
- 19 September 2014
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 7 (5) , 410-413
Bowel-associated dermatosis − arthritis syndrome in a patient with ulcerative colitis: an extraintestinal manifestation of inflammatory bowel disease
Bowel-associated dermatosis − arthritis syndrome (BADAS) is a neutrophilic dermatosis characterized by cutaneous lesions that begin as erythematous macules and progress to vesiculopustular eruptions. It has been described in patients with inflammatory bowel disease as well as those who have undergone various intestinal surgeries. Pathologically, the lesions show features of vasculitis without fibrinoid necrosis. In a patient with diagnosed inflammatory bowel disease, these neutrophilic dermatoses should be viewed as external signals of bowel inflammation. Management requires long-term treatment of the underlying disease. We report a case of BADAS in a patient with ulcerative colitis in which the skin lesions were associated with increased colonic inflammation.